Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Overcoming TKI resistance in a lung xenograft model

ABSTRACT: Overcoming TKI resistance in a lung xenograft model

PROVIDER: PRJNA678755 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR13069441_1.fastq.gz	Fastqsanger.gz
	SRR13069441_2.fastq.gz	Fastqsanger.gz
	SRR13069442_1.fastq.gz	Fastqsanger.gz
	SRR13069442_2.fastq.gz	Fastqsanger.gz
	SRR13069443_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 26

Similar Datasets

Overcoming TKI resistance in a lung xenograft model

Project description:Bulk RNA-Seq of PC9 xenograft tumors in different stages of response and resistance to Erlotinib treatment. A combination treatment is proposed in order to overcome Erlotinib drug resistance.

2020-11-17 | GSE161584 | GEO

TFF3 drives Hippo dependent EGFR-TKI resistance in lung adenocarcinoma

Project description:Intrinsic and acquired resistance represent major obstacles to optimize outcomes in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) targeted therapy in lung adenocarcinoma (LUAD). Hence, a deeper understanding of EGFR-TKI resistance mechanisms in LUAD will potentially assist in formulating strategies to delay or overcome such resistance. Herein, it was observed that trefoil factor 3 (TFF3) is a crucial mediator of the LUAD EGFR-TKI response. TFF3 conferred intrinsic resistance to EGFR inhibition in LUAD by promotion of EGFR activation. TFF3 expression was also increased in acquired EGFR-TKI resistant LUAD, accompanied by reduced EGFR activation. YAP, a key mediator of the Hippo signaling, was positively regulated by TFF3 by post-transcriptional mechanisms and was responsible for acquired EGFR-TKI resistance mediated by TFF3. Inhibition of TFF3 by a small molecule inhibitor not only enhanced EGFR-TKI sensitivity in LUAD cells but also restored the sensitivity of acquired EGFR-TKI resistant LUAD cells to EGFR-TKIs in vitro and in vivo. These findings demonstrate a pivotal function of TFF3 in mediating EGFR-TKI resistance in LUAD and may offer a potential therapeutic mechanism for delaying or overcoming resistance to EGFR-TKIs.

2025-10-31 | GSE276990 | GEO

Effects of magnolin and chloroform parts of Flos Magnoliae on gene expression in NCI-H1975 cells,and genetic changes after EGFR TKI resistance

Project description:we demonstrated that N-Myc Downstream Regulated 1 (NDRG1) interacts with and restrains Neuregulin 2 (NRG2) to down-regulate the EGFR. This inhibition prevents excessive autophagy protection, thereby reducing EGFR TKI drug resistance in lung cancer cell lines and xenograft mouse models. Activation of NDRG1 using compounds like Chinese herb extract Flos Magnoliae and its active monomer (magnolin) restored sensitivity in resistant cell lines to EGFR TKIs and delayed resistance in lung cancer xenograft mice. These findings highlight a mechanism for resistance to a molecularly targeted therapy and provide a potential therapeutic target for overcoming resistance to EGFR TKIs, including the second-generation inhibitor afatinib

2025-09-16 | GSE277007 | GEO

Microarray expression profile of long noncoding RNAs in EGFR-TKI resistance of lung adenocarcinoma

Project description:Lung adenocarcinoma cells harboring epidermal growth factor receptor (EGFR) mutations are sensitive to EGFR tyrosine kinase inhibitors (TKIs). Prolonged cancer treatment will induce the development of acquired resistance to EGFR TKI. To gain insight into the molecular mechanisms of EGFR-TKIs resistance, we generate EGFR-TKI-resistant HCC827-8-1 cells to be analyzed by microarray with their parental HCC827cells. gefitinib resistant HCC827-8-1 cells with three replications; gefitinib-sensitive HCC827 cells with three replications

2016-08-23 | E-GEOD-74575 | biostudies-arrayexpress

Dauricine regulates SAT1 to induce ferroptosis and overcome osimertinib resistance in Non-small cell lung cancer

Project description:Targeted tyrosine kinase inhibitors (TKIs) play a crucial role in the treatment of lung cancer; however, nearly all patients face the challenge of TKI resistance. Unraveling the molecular mechanisms of TKI resistance and effectively addressing it is a pressing clinical issue. We have successfully established a third-generation TKI-resistant lung cancer cell line and organoids, and identified batatasin alkaloid from 302 traditional Chinese medicines as capable of effectively overcoming osimertinib resistance. Our scientific hypothesis posits that batatasin alkaloid improves osimertinib resistance by modulating ACSL1 to influence lipid peroxidation-induced ferroptosis. This project aims to utilize various lung cancer models to elucidate the relationship between osimertinib resistance and ferroptosis in lung cancer, uncover the specific molecular mechanisms by which batatasin alkaloid regulates ACSL1, and explore the feasibility of batatasin alkaloid in improving osimertinib resistance. This project will unveil novel molecular mechanisms of TKI resistance in lung cancer and explore the application of traditional Chinese medicine in overcoming resistance to targeted therapy for lung cancer.

2025-08-06 | GSE276807 | GEO

MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer

Project description:Here we identified a role for the lncRNA MYLK-AS1 promoting acquired TKI resistance of lung cancer in vitro and in vivo. MYLK-AS1 bound and directly drove phase separation of interleukin enhancer binding factor 3 (ILF3), thus interacting with the 3’UTR of glutamate dehydrogenase 1 (GLUD1) to post-transcriptionally promote its mRNA stability, thus enhancing mitochondrial glutamine catabolism, promoting TKI resistance. The MYLK-AS1/ILF3/GLUD1 may be a target for overcoming TKI resistance in lung cancer.

2025-04-28 | GSE295807 | GEO

Microarray expression profile of long noncoding RNAs in EGFR-TKI resistance of lung adenocarcinoma

2016-08-23 | GSE74575 | GEO

YAP activation mediates acquired resistance to ALK inhibitor in ALK rearranged non–small cell lung cancer

Project description:To investigate a possible candidate for overcoming the acquired resistance to ALK-TKI, we established an in vitro model of acquired resistance to crizotinib (H3122-CR) by exposing EML4-ALK–positive H3122 lung cancer cells to increasing doses of crizotinib.

2019-12-31 | GSE117181 | GEO

TFF3 drives Hippo dependent EGFR-TKI resistance in lung adenocarcinoma

Project description:TFF3 drives Hippo dependent EGFR-TKI resistance in lung adenocarcinoma

| PRJNA1160153 | ENA

TKI

Project description:TKI

| PRJEB37289 | ENA